Compare iShares Core S&P 500 ETF (IVV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Novartis AG — how do they compare? iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: iShares Core S&P 500 ETF is far larger — about 3.3× Novartis AG's market cap, and Novartis AG pays a 3.31% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Novartis AG for 82 Days on average.
| IVV | NVS | |
|---|---|---|
Market Cap | $897.20B | $268.57B |
Volume | 4,580,672 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $168.62 |
52-Week Low | $634.93 | $121.80 |
Typical Hold Time | 46 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.97 with a slight 0.18% daily gain. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights mixed sentiment with concerns about profit growth slowing from 35% in 2026 to 15% in 2027 (24/7 Wall Street, 2026-10-03), though some analysts project a year-end rally (Citadel strategist, 2026-10-02). The ETF remains a core holding for broad market exposure amid ongoing economic uncertainties.
The outlook for IVV is cautiously optimistic, supported by bullish technicals and historical seasonal patterns. Key opportunities include potential upside from AI-driven earnings growth and index composition changes like Twilio's addition (Market Watch, 2026-10-01). Risks center on concentration in top holdings, rising interest rates, and geopolitical tensions that could dampen broader market performance. Investors should weigh the ETF's low-cost diversification against macroeconomic headwinds.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
